Enanta Pharmaceuticals | ENTA - Debt


Enanta Pharmaceuticals reported $1.35M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Amgen USD 54.6B 17M Dec/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 312.77M 53.52M Dec/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 6.56B 275.1M Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Gilead Sciences USD 24.94B 5M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Immunic USD 0 0 Jun/2024
Incyte USD 39.43M 982K Mar/2026
Insmed USD 727.62M 275K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
J&J USD 54.99B 7.05B Mar/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 451.49M 494K Dec/2025
Merck USD 49.34B 7.97B Dec/2025
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 47B 11.62B Mar/2026
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 63.73B 231M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026